SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS) today announced the presentation of an analysis of pooled data from its two Phase III clinical studies indicating that the investigational drug budesonide MMX® 9 mg taken once daily for the induction of remission of mild or moderate active ulcerative colitis was statistically superior to placebo in clinical and endoscopic remission and in symptom resolution. Santarus also announced that it has selected UCERIS™ as the proprietary trade name for budesonide MMX.
